Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): final report
Kidney Research and Clinical Practice · 01.03.2026 · 45 (2) · 220-231
DOI: 10.23876/j.krcp.24.067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Research and Clinical Practice, erschienen am 01.03.2026. Verfasst von Hayne Cho Park und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Tolvaptan, a selective vasopressin V2 receptor antagonist, was first approved by the Korean Ministry of Food and Drug Safety in 2015 as a treatment option for autosomal dominant polycystic kidney disease (ADPKD). To prescribe tolvaptan safely and effectively, we designed the phase 4 clinical trial among Korean ADPKD patients with chronic kidney disease stages 1 to 3.
Methods
A total of 117 Korean patients aged 19 to 50 years with rapidly progressing ADPKD were enrolled in the study. Tolvaptan was prescribed for 24 months with the maximum tolerable dose up to 120 mg/day. The primary outcome was the incidence of treatment-emergent adverse events (TEAEs) including hepatic adverse events. The secondary outcomes were the annual mean percent change of total kidney volume (TKV) and the annual mean change of estimated glomerular filtration rate (eGFR).
Results
A total of 489 TEAEs occurred in 106 patients (90.6%). A total of 17 cases of hepatic adverse events (14.5%) occurred during the study period and mostly within the first 18-month period. However, liver enzymes were normalized after drug discontinuation. Although it was not statistically significant, patients with a previous history of liver disease as well as those with mild elevation of liver enzyme showed a higher frequency of hepatic adverse events. Compared with the predicted value from the calculation, tolvaptan attenuated both TKV growth and eGFR decline rate.
Conclusion
Although the incidence of hepatic adverse events was higher in Korean ADPKD patients compared to the previous studies, tolvaptan can be prescribed safely and effectively using meticulous titration and 1-month interval monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea.
- Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
- Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
- Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Zitieren
APA
Park, H. C., Kim, Y. C., Kim, H., Kim, Y., Ryu, H. J., Kim, Y. S., Chung, W., Kim, Y. L., Han, S., Jung, Y., Shin, H. S., Na, K. Y., Lee, K. B., Park, H. C., Han, S. H., Yoo, T. H., Kim, Y. H., Kim, S. W., Lee, K. W., …, & Oh, Y. K. (2026). Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): final report. Kidney Research and Clinical Practice, 45(2), 220-231. https://doi.org/10.23876/j.krcp.24.067
Vancouver
Park HC, Kim YC, Kim H, Kim Y, Ryu HJ, Kim YS, et al. Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): final report. Kidney Research and Clinical Practice. 2026;45(2):220-231. doi:10.23876/j.krcp.24.067
BibTeX
@article{Park2026,
author = {Park, Hayne Cho and Kim, Yong Chul and Kim, Hyunsuk and Kim, Yaerim and Ryu, Hyun Jin and Kim, Yong Soo and Chung, Wookyung and Kim, Yong-Lim and Han, Seungyeup and Jung, Yeonsoon and Shin, Ho Sik and Na, Ki Young and Lee, Kyu Beck and Park, Hyeong Cheon and Han, Seung Hyeok and Yoo, Tae-Hyun and Kim, Yeong Hoon and Kim, Soo Wan and Lee, Kang Wook and Kim, Sung Gyun and Lee, Chang Hwa and Bae, Kyongtae T and Oh, Kook Hwan and Ahn, Curie and Oh, Yun Kyu},
title = {Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): final report},
journal = {Kidney Research and Clinical Practice},
year = {2026},
volume = {45},
number = {2},
pages = {220--231},
doi = {10.23876/j.krcp.24.067}
}
EUVIMED